ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease
Details
Publication Year 2023-12,Volume 53,Issue #12,Page 2319-2329
Journal Title
Internal Medicine Journal
Publication Type
Guideline
Abstract
This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.
Publisher
Wiley
Keywords
Humans; *Bronchiolitis Obliterans Syndrome; Consensus; *Hematopoietic Stem Cell Transplantation; Steroids/therapeutic use; Nitriles; Adrenal Cortex Hormones/therapeutic use; *Graft vs Host Disease/drug therapy; Acute Disease; Chronic Disease; GvHD; acute; chronic; graft-versus-host disease; ruxolitinib
Department(s)
Clinical Haematology
Open Access at Publisher's Site
https://doi.org/10.1111/imj.16255
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-01-18 07:06:24
Last Modified: 2024-01-18 07:06:48

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙